Achillion Pharmaceuticals

INVESTORS

Press Releases

 
Press Releases
  Date Title View
Sep 17, 2015
- 100% SVR12 reported for all patients treated for six- (n=18) or eight-weeks (n=12) — - Odalasvir (ACH-3102) is the subject of an exclusive, worldwide development and commercialization license granted to Janssen - NEW HAVEN, Conn., Sept. 17, 201...
PDF
Sep 1, 2015
NEW HAVEN, Conn., Sept. 01, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Baird 2015 Healthcare Conferenc...
PDF
Aug 10, 2015
NEW HAVEN, Conn., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three and six months ended June 30, 2015. For the second quarter of 2015, Achillion reported a net loss of $29.0 million or $0.25 per share, compared with a net loss of $15.7 million or $...
PDF
Aug 3, 2015
NEW HAVEN, Conn., Aug. 03, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Alios Biopharma Inc., part of the Janssen Pharmaceutical Companies (Janssen) has initiated a phase I clinical trial to evaluate the potential effect of simeprevir and odalasvir (also known as ACH-3102) on th...
PDF
Jun 18, 2015
NEW HAVEN, Conn., June 18, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that members of the senior management team will present a corporate overview at the JMP Securities Life Sciences Conference on Tuesday, June 23, 2015 at 9:00 a.m. ET at The St. Regis New York Hotel in New York, N...
PDF
May 19, 2015
- Transactions include up to $1.1 billion in potential development, regulatory and sales milestone payments and a separate equity investment -- Achillion eligible for tieredroyalties between mid-teens and low-twenties on future worldwide sales -- Janssen responsible for all development costs within the collaboration and all subsequent costs related...
PDF
May 7, 2015
NEW HAVEN, Conn., May 7, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2015. For the first quarter of 2015, the Company reported a net loss of $19.3 million or $0.17 per share, compared with a net loss of $16.1 million or $0.17 per share for the first qua...
PDF
Apr 30, 2015
NEW HAVEN, Conn., April 30, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences: Deutsche Bank 40th Annual Health Care Conference on Thursday, May 7, 2015 at...
PDF
Apr 25, 2015
- Two late breaker presentations detail previously announced 100% SVR12 in Phase 2 trial evaluating 6- or 8-weeks of treatment with ACH-3102 and sofosbuvir in genotype 1 HCV patients and Phase 1 proof-of-concept results with ACH-3422 -- Clinical virology presentation continues to support improved barrier to resistance with ACH-3102 - VIENNA, Au...
PDF
Apr 8, 2015
NEW HAVEN, Conn., April 8, 2015 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it will present three posters, including two late breaker abstracts, at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will i...
PDF
FirstPrevious
...
7
...
NextLast